Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus
cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and
toxicity in patients with Stage IIB or III squamous cell esophageal carcinoma.